170569-86-5

中文名稱 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-

英文名稱 4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE

CAS 170569-86-5

分子式 C16H11ClF3N3O2S

分子量 401.79

MOL 文件 170569-86-5.mol

更新日期 2026/07/13 18:35:43

170569-86-5 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-價格(試劑級) 常見問題列表

基本信息

中文別名

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-吡唑-1-基)苯磺酰胺

英文別名

SC-236
SC-58236
SC 236 - SC 58236
4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-

物理化學(xué)性質(zhì)

熔點146-148°C

沸點543.4±60.0 °C(Predicted)

密度1.54±0.1 g/cm3(Predicted)

儲存條件2-8°C

溶解度二甲基亞砜：>20mg/mL

酸度系數(shù)(pKa)9.66±0.10(Predicted)

形態(tài)粉末

顏色白色至灰白色

InChI1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

InChIKeyNSQNZEUFHPTJME-UHFFFAOYSA-N

SMILESNS(=O)(=O)c1ccc(cc1)-n2nc(cc2-c3ccc(Cl)cc3)C(F)(F)F

安全數(shù)據(jù)

危險性符號(GHS) 有毒 (GHS06)

GHS06

警示詞危險

危險性描述H301

防范說明P264-P270-P301+P310-P405-P501

危險品標(biāo)志T

危險類別碼25

安全說明45

危險品運輸編號UN 2811 6.1 / PGIII

WGK Germany3

存儲類別6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects

危險性類別Acute Tox. 3 Oral

圖譜信息

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-(170569-86-5)核磁圖(¹HNMR)

4-(5-(4-氯苯基)-3-(三氟甲基)-1H-價格(試劑級)

報價日期	產(chǎn)品編號	產(chǎn)品名稱	CAS號	包裝	價格
2026/07/06	S0762	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC 236	170569-86-5	5mg	2841.93元
2026/07/06	S0762	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC 236	170569-86-5	25mg	8591.31元
2026/06/05	HY-W010983	4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236	170569-86-5	5mg	800元

常見問題列表

生物活性

SC-236 是具有口服活性的 COX-2 特異性抑制劑 (對 COX-1 的 IC50 值為 10 nM)和 PPARγ 激動劑。SC-236 可通過 c-Jun 氨基端抑制激活蛋白-1 (AP-1) 活性。SC-236在小鼠模型中通過抑制 ERK 的磷酸化發(fā)揮抗炎作用。

靶點

COX-2

10 nM (IC ₅₀ )

COX-1

17.8 μM (IC ₅₀ )

體外研究

SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.

Western Blot Analysis

Cell Line:	vECs.
Concentration:	15 μM
Incubation Time:	30 min.
Result:	Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs.